Viatris Past Earnings Performance
Past criteria checks 0/6
Viatris has been growing earnings at an average annual rate of 21.8%, while the Pharmaceuticals industry saw earnings growing at 6.2% annually. Revenues have been growing at an average rate of 6.3% per year.
Key information
21.8%
Earnings growth rate
20.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 6.3% |
| Return on equity | -4.5% |
| Net Margin | -5.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Viatris makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 15,049 | -883 | 3,666 | 802 |
| 30 Jun 24 | 15,239 | -646 | 3,728 | 814 |
| 31 Mar 24 | 15,361 | -56 | 3,766 | 819 |
| 31 Dec 23 | 15,427 | 55 | 3,753 | 802 |
| 30 Sep 23 | 15,466 | 1,832 | 3,720 | 782 |
| 30 Jun 23 | 15,602 | 1,854 | 3,686 | 746 |
| 31 Mar 23 | 15,800 | 1,904 | 3,580 | 700 |
| 31 Dec 22 | 16,263 | 2,079 | 3,518 | 661 |
| 30 Sep 22 | 16,728 | 804 | 3,584 | 745 |
| 30 Jun 22 | 17,187 | 761 | 3,678 | 719 |
| 31 Mar 22 | 17,648 | 168 | 4,101 | 711 |
| 31 Dec 21 | 17,886 | -1,269 | 4,245 | 668 |
| 30 Sep 21 | 17,168 | -1,921 | 4,802 | 625 |
| 30 Jun 21 | 15,604 | -2,047 | 4,382 | 603 |
| 31 Mar 21 | 13,757 | -1,728 | 3,686 | 565 |
| 31 Dec 20 | 11,946 | -670 | 2,686 | 550 |
| 30 Sep 20 | 11,514 | 266 | 2,445 | 486 |
| 30 Jun 20 | 11,504 | 271 | 2,427 | 487 |
| 31 Mar 20 | 11,624 | 63 | 2,503 | 492 |
| 31 Dec 19 | 11,501 | 17 | 2,503 | 519 |
| 30 Sep 19 | 11,387 | 48 | 2,445 | 519 |
| 30 Jun 19 | 11,288 | 34 | 2,452 | 532 |
| 31 Mar 19 | 11,245 | 240 | 2,378 | 568 |
| 31 Dec 18 | 11,434 | 353 | 2,397 | 586 |
| 30 Sep 18 | 11,594 | 546 | 2,303 | 622 |
| 30 Jun 18 | 11,719 | 457 | 2,385 | 648 |
| 31 Mar 18 | 11,873 | 717 | 2,435 | 663 |
| 31 Dec 17 | 11,908 | 696 | 2,564 | 666 |
| 30 Sep 17 | 11,937 | 869 | 2,357 | 655 |
| 30 Jun 17 | 12,007 | 661 | 2,356 | 665 |
| 31 Mar 17 | 11,605 | 533 | 2,300 | 663 |
| 31 Dec 16 | 11,077 | 480 | 2,351 | 698 |
| 30 Sep 16 | 10,300 | 257 | 2,150 | 691 |
| 30 Jun 16 | 9,938 | 806 | 2,019 | 688 |
| 31 Mar 16 | 9,749 | 805 | 1,973 | 687 |
| 31 Dec 15 | 9,429 | 848 | 1,924 | 652 |
| 30 Sep 15 | 9,021 | 842 | 1,885 | 645 |
| 30 Jun 15 | 8,410 | 913 | 1,767 | 628 |
| 31 Mar 15 | 7,876 | 870 | 1,616 | 599 |
| 31 Dec 14 | 7,720 | 929 | 1,499 | 564 |
| 30 Sep 14 | 7,445 | 920 | 1,474 | 544 |
| 30 Jun 14 | 7,129 | 580 | 1,398 | 499 |
| 31 Mar 14 | 6,993 | 633 | 1,326 | 470 |
| 31 Dec 13 | 6,909 | 624 | 1,338 | 456 |
Quality Earnings: VTRS * is currently unprofitable.
Growing Profit Margin: VTRS * is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VTRS * is unprofitable, but has reduced losses over the past 5 years at a rate of 21.8% per year.
Accelerating Growth: Unable to compare VTRS *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VTRS * is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.5%).
Return on Equity
High ROE: VTRS * has a negative Return on Equity (-4.46%), as it is currently unprofitable.